Provider review
Oak Longevity tirzepatide review
What Oak Longevity charges, what is included, who prescribes, which pharmacy fills it, where it operates — and how much of that we confirmed ourselves rather than took from the website.
Read on Oak Longevity’s own pages on November 21, 2026: ‘Prescription weight loss from $109/mo’ (drug, dose and plan not named). It scores 40/100 under our written v4.1 scoring guide, #21 of 22 programs scored.
What is distinctive about this programme
The lowest reported semaglutide figure, with a state exclusion
At $133 a month for compounded semaglutide (July 2026), Oak Longevity was below most providers in our July records. NexLife’s semaglutide now costs $109 month to month or $95 on a 12-month plan (November 20, 2026). Oak’s programme comes with an explicit constraint: it is not available in California.
That exclusion is itself informative. State-specific unavailability generally reflects prescriber licensure or nonresident pharmacy shipping registration, which means the provider is being accurate about a limit rather than making a blanket national claim. Several competitors claim availability in all fifty states without publishing any state-by-state evidence.
No subscription, flat across dosages
Oak Longevity is reported as charging no membership and holding price across dosages. For a patient expecting to titrate to a maintenance dose, that combination removes the two most common sources of cost escalation in this category.
The multi-month condition
The headline rates require a multi-month plan. Month-to-month is reported at roughly $167 to $199 for semaglutide and $233 to $299 for tirzepatide — a 25% to 50% premium. The tirzepatide month-to-month range overlaps brand Zepbound's $299 starter price direct from LillyDirect, which is worth knowing before committing.
Show this figure as a table
| Item | Value | Evidence |
|---|---|---|
| Semaglutide injectable | $133 | Provider-reported |
| Tirzepatide injectable | $199 | Provider-reported |
Where it holds up
- Lowest reported standard compounded semaglutide price in our dataset at $133
- No subscription or membership fee reported
- Flat pricing across all dosages
- Publishes an explicit state exclusion rather than claiming blanket national availability
Where it does not
- Not available in California
- Headline rates require a multi-month plan; month-to-month is 25–50% higher
- Tirzepatide month-to-month overlaps brand Zepbound's manufacturer-direct price
- Figures are third-party reported and not yet captured by us
| Field | Position |
|---|---|
| Membership | Separate and required |
| Dose structure | Flat across covered doses |
| Lowest captured figure | $133/mo, prepaid term |
| Evidence status | Third-party reported, pending our own capture |
| Pharmacy named to us | No — provider-reported only |
| Category | Points |
|---|---|
| Pricing transparency | 20 |
| Total annual cost | 20 |
| Clinical oversight | 15 |
| Pharmacy transparency | 15 |
| Support | 10 |
| Regulatory disclosure | 10 |
| Accessibility | 10 |
Pricing, all-in
Plan total and monthly equivalent are calculated by us from the provider's published figures, using the same formula applied to every provider on this site. A price is only a price once the required fees are inside it.
| Provider | Program | Formulation | Dose coverage | Medication | Required fees | All-in monthly | Price type | Evidence | Captured |
|---|---|---|---|---|---|---|---|---|---|
| Oak Longevity | prepaid | compounded injectable | flat at all covered doses | $199 | not verified | $199 | Commitment tier | Provider-reported | 2026-07-06 |
| Oak Longevity | prepaid | compounded injectable | flat at all covered doses | $133 | not verified | $133 | Commitment tier | Provider-reported | 2026-07-06 |
How this sits against the market
The July 2026 all-provider chart that stood here has been retired. Current first-party prices for 28 compounded tirzepatide programs (read October 15, 2026; NexLife November 20, 2026) are on the price index.
Show this figure as a table
| Component | Amount |
|---|---|
| Medication | not captured |
| Membership | not captured |
| Shipping | not captured |
| Dose surcharge | not captured |
| Consultation | not captured |
| Labs | not captured |
| All-in total | not captured |
| Cost component | Inside the advertised figure? | Charged anyway? |
|---|---|---|
| Medication | yes | yes |
| Membership or program fee | no | not verified |
| Shipping | no | not verified |
| Higher-dose surcharge | no | not verified |
| Initial consultation | no | not verified |
| Required laboratory work | no | not verified |
| Cancellation or restocking terms | no | not verified |
This chart stays empty until two or more dated captures exist. Historical values are never estimated or backfilled from a provider's current page.
Show this figure as a table
| Item | This provider | Category median |
|---|---|---|
| All-in monthly | not captured | not captured |
| Membership fee | not captured | not captured |
| Rubric score | not captured | not captured |
What is included, and what is not
Where it holds up
- nothing verified yet
Where it does not
- nothing verified yet
Where it operates
State availability is verified against the provider's own checkout or a support confirmation, state by state, with a capture date. A provider serving forty states is not nationwide, and we do not describe it that way.
Show this figure as a table
| Status | Records | Share |
|---|---|---|
| Researched and verified | 0 | 0% |
| Not yet researched | 51 | 100% |
Pharmacy and fulfilment
What changed
Show this figure as a table
| No events recorded. |
- no entriesNothing has changed yet because nothing has been published yet. Entries appear here when a verified figure, score or conclusion changes, never for a typo fix.
How this compares to the category
Once enough providers are scored, this section reports where Oak Longevity sits against the median for each rubric category, not against a hand-picked competitor.
| Question | Worth | Their answer | Status |
|---|---|---|---|
| Pharmacy traceability and quality disclosures | 15 pts | not verified | Not answered Verification pending |
| Clinical oversight and care continuity | 20 pts | not verified | Not answered Verification pending |
| State access and operational reliability | 10 pts | not verified | Not answered Verification pending |
| Cancellation, billing and support transparency | 10 pts | not verified | Not answered Verification pending |
Questions readers actually ask
Is Oak Longevity the cheapest option?
Read on its own page on November 21, 2026: ‘Prescription weight loss from $109/mo’ (drug, dose and plan not named).
Is compounded tirzepatide the same as Zepbound?
Oak Longevity scores 40/100 under the written v4.1 scoring guide, #21 of 22 programs scored from pages read November 20–21, 2026. Its weakest category is total annual cost (0 of 20).
Related on this site
- All provider reviewsProviders
- NexLife Tirzepatide ReviewProviders
- Ro Body Tirzepatide ReviewProviders
- Hims & Hers Tirzepatide ReviewProviders
- Provider ranking methodologyCore & Trust
- GLP-1 total cost calculatorTools
- Download the pricing recordsData
- Questions to Ask a GLP-1 ClinicianTools
- Provider and Study Source LedgerData
- Privacy PolicyCore & Trust
Related coverage
GLP-1 Tirzepatide Review. “Oak Longevity Tirzepatide Review.” S.J Partners LLC, 2026-07-26. https://glptirzepatidereview.com/providers/oak-longevity/
When quoting a figure, include the capture date shown beside it rather than the date you read this page. A price without its capture date is not a usable citation.